{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0016049",
      "entity_text" : "cell growth",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ08249",
      "entity_text" : "BPQD-LSD1 siRNA complex",
      "entity_type" : "protein"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "The BPQD-LSD1 siRNA complex exhibited superior transfection efficiency compared to commercial delivery reagents (e.g., Lipofectamine 2000 and Oligofectamine) and was able to inhibit the cell growth rate by> 80% in combination with NIR light with negligible cytotoxicity, indicating the potential of applying BPQD for siRNA delivery and cancer therapy.",
  "reading_complete" : "2020-08-02T18:12:23Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T18:08:49Z",
  "trigger" : "inhibit",
  "evidence" : [ "BPQD-LSD1 siRNA complex exhibited superior transfection efficiency compared to commercial delivery reagents (e.g., Lipofectamine 2000 and Oligofectamine) and was able to inhibit the cell growth" ],
  "pmc_id" : "5817107",
  "score" : 0
}